In this study, four novel compounds were synthesized and evaluated for their antifungal activity against three clinically significant Candida strains, including Candida albicans BDU MI-44, Candida guilliermondii BDU-217 and Candida tropicalis BDU LK-30. All compounds were tested at a uniform concentration of 0.3%, and their antifungal efficacy was assessed through the agar well diffusion method. The inhibition zones ranged from 11.0 mm to 24.1 mm, indicating varying degrees of antifungal activity. Among the tested strains, C. tropicalis BDU LK-30 was the most susceptible to all four compounds. The compound methyl (Z)-2-(4-(tert-butyl) phenyl)-2-(2-(p-tolyl) hydrazineylidene) acetate (Compound II) demonstrated the highest antifungal potency, producing an inhibition zone of 24.1 mm against C. tropicalis, and consistently outperformed the other compounds across all tested strains. Comparative analysis revealed that hydrazineylidene acetate moieties significantly enhance antifungal activity. Overall, the results highlight the potential of these synthesized compounds, particularly compound II as promising antifungal agents, with selective and enhanced activity against Candida species.